INT235996

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.09
First Reported 2008
Last Reported 2008
Negated 1
Speculated 0
Reported most in Body
Documents 3
Total Number 4
Disease Relevance 1.29
Pain Relevance 0.58

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Src) enzyme binding (Src) response to stress (Src)
cytoplasm (Src) cytosol (Src) cell proliferation (Src)
Src (Rattus norvegicus)
Pain Link Frequency Relevance Heat
5HT 90 99.08 Very High Very High Very High
Arthritis 20 92.40 High High
Inflammation 42 50.00 Quite Low
cytokine 22 18.48 Low Low
Bioavailability 8 18.48 Low Low
Serotonin 62 5.00 Very Low Very Low Very Low
fluoxetine 48 5.00 Very Low Very Low Very Low
Pyramidal cell 40 5.00 Very Low Very Low Very Low
agonist 30 5.00 Very Low Very Low Very Low
antagonist 22 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Myeloid Leukemia 2 99.68 Very High Very High Very High
Chronic Myeloid Leukemia 2 99.58 Very High Very High Very High
Arthritis 20 92.40 High High
Pressure And Volume Under Development 10 88.84 High High
Experimental Arthritis 2 70.16 Quite High
Disease 10 66.96 Quite High
Cancer 8 55.16 Quite High
INFLAMMATION 40 50.00 Quite Low
Middle Cerebral Artery Infarction 2 48.56 Quite Low
Organ Transplantation 8 38.64 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Compound 23, a close structural analog of dasatinib (BMS-354825), a marketed kinase inhibitor drug for the treatment of chronic myelogenous leukemia (CML), is a potent, selective, and ATP-competitive inhibitor of Lck and other Src family kinases (IC50?
Negative_regulation (inhibitor) of Gene_expression (selective) of Src associated with myeloid leukemia and chronic myeloid leukemia
1) Confidence 0.09 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.65 Pain Relevance 0.08
Compound 23, a close structural analog of dasatinib (BMS-354825), a marketed kinase inhibitor drug for the treatment of chronic myelogenous leukemia (CML), is a potent, selective, and ATP-competitive inhibitor of Lck and other Src family kinases (IC50?
Negative_regulation (inhibitor) of Gene_expression (other) of Src associated with myeloid leukemia and chronic myeloid leukemia
2) Confidence 0.09 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.64 Pain Relevance 0.08
m, 3 min) in the absence or presence of the Src kinase inhibitor PP2 or its inactive homolog PP3 (both 10 ?
Negative_regulation (inhibitor) of Gene_expression (kinase) of Src
3) Confidence 0.06 Published 2008 Journal The Journal of Biological Chemistry Section Body Doc Link PMC2427346 Disease Relevance 0 Pain Relevance 0.21
m, 3 min) in the absence or presence of the Src kinase inhibitor PP2 or its inactive homolog PP3 (both 10 ?
Negative_regulation (presence) of Neg (absence) Gene_expression (absence) of Src
4) Confidence 0.06 Published 2008 Journal The Journal of Biological Chemistry Section Body Doc Link PMC2427346 Disease Relevance 0 Pain Relevance 0.21

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox